Sherman Antitrust Act: Primary federal antitrust law that prohibits anticompetitive business practices and monopolistic conduct. Critical for ensuring reverse payment agreements don't violate antitrust provisions.

Federal Trade Commission Act: Empowers the FTC to prevent unfair methods of competition and deceptive practices. Key in regulating and monitoring reverse payment agreements.

Clayton Act: Supplements the Sherman Act by prohibiting specific anticompetitive practices. Relevant for reviewing the competitive effects of reverse payment agreements.

Hatch-Waxman Act: Drug Price Competition and Patent Term Restoration Act - Establishes framework for generic drug approval and patent challenges, fundamental to reverse payment agreement context.

Patent Act (35 U.S.C.): Federal patent law governing patent rights and enforcement, essential for understanding the underlying patent disputes in reverse payment agreements.

FTC v. Actavis (2013): Landmark Supreme Court decision establishing that reverse payment agreements are subject to rule of reason analysis under antitrust law.

Medicare Modernization Act of 2003: Requires pharmaceutical companies to file patent settlements with the FTC, including reverse payment agreements.

State Antitrust Laws: Various state-specific antitrust regulations that may affect the enforceability and terms of reverse payment agreements.

Hart-Scott-Rodino Act: Requires companies to file notifications with FTC and DOJ for certain transactions, potentially applicable to significant reverse payment agreements.

FDA Regulations: Federal drug regulations that govern pharmaceutical product approval, marketing, and competition, providing regulatory context for reverse payment agreements.